X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Kura's lead product KO-2806, which is a Ftase inhibitor got dosing of the first patient in Phase I clinical trial studies in combination with cabozantinib for the treatment of Renal Cell Carcinoma.
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with Cabometyx (cabozantinib) for the treatment of first-line advanced renal cell carcinoma.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutantion non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutant non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
Cabometyx (Cabozantinib) tablet is a Mmultiple Rreceptor tyrosine kinases inhibitor, which is investigated for the treatment of advanced pancreatic and extra-pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
Cabometyx (Cabozantinib) tablet is a multiple receptor tyrosine kinases inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
AVB-S6-500 (batiraxcept), is an ultra-high affinity decoy protein that binds to GAS6, the ligand that activates AXL, hence inhibits the metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. It is being investigated for clear cell renal cell carcinoma.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Cabometyx (cabozantinib) is a multiple receptor tyrosine kinases inhibitor. These receptors are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, maintenance of the tumor microenvironment, etc.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
AVB-500 (batiraxcept), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Cabometyx (cabozantinib) is a multiple receptor tyrosine kinases inhibitor. These receptors are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, maintenance of the tumor microenvironment, etc.
Lead Product(s): Cabozantinib,Nivolumab,Sunitinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. It is being investigated in combination with cabometyx (cabozantinib) for advanced renal cell carcinoma.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Cabometyx is a multi-targeted tyrosine kinase inhibitor (TKI) with targets including vascular endothelial growth factor receptor (VEGFR), c-MET and the TAM receptor family, which block the growth of cancer.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
AVB-S6-500 (batiraxcept), for treatment of patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology (IO)-based and VEGF-TKI-based therapies.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Cabometyx (cabozantinib) in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab.
Lead Product(s): Cabozantinib,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
At a prespecified interim analysis for the secondary endpoint of overall survival (OS), the combination of Cabometyx (cabozantinib), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab did not demonstrate a significant benefit.
Lead Product(s): Cabozantinib,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Trial met primary endpoint of ORR, cabozantinib (CABOMETYX) per response evaluation criteria in solid tumor version 1.1 at 54%. Overall clinical benefit rate was 91%. At median follow-up of 10.6 months, PFS rate was 54.0%, and median progression-free survival was 14.6 months.
Lead Product(s): Cabozantinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Cabometyx (Cabozantinib) in combination with atezolizumab demonstrated encouraging activity with a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma and patients with previously treated advanced NSCLC.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Updated outcomes from trial evaluating combination of Cabometyx (Cabozantinib) plus atezolizumab in an expanded patient population in NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhibitor.
Lead Product(s): Cabozantinib,Nivolumab,Sunitinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
AVB-S6-500 (Batiraxcept) 15 mg/kg in combination with cabozantinib 60 mg has a manageable safety profile in previously treated ccRCC; no dose-limiting toxicities have been observed; a similar safety profile was observed across the 15 mg/kg and 20 mg/kg dose cohorts.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
EC approval is based on results from COSMIC-311, trial that demonstrated significant improvement in progression-free survival with CABOMETYX (cabozantinib s-malate) versus placebo in patients with RAI-DTC who progressed after up to two prior VEGFR-targeted therapies.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
Batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
CHMP recommendation is based on results from COSMIC-311 trial that demonstrated significant improvement in progression-free survival (PFS) with CABOMETYX versus placebo in patients with RAI-refractory DTC who progressed after up to two prior VEGFR-targeted therapies.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
Final analysis showed neither improvement nor detriment in OS for cabozantinib in combination with atezolizumab versus sorafenib. Based on this outcome for OS and rapidly evolving treatment landscape for advanced HCC, Exelixis does not intend to submit an sNDA to the U.S.FDA.
Lead Product(s): Cabozantinib,Atezolizumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
Positive results demonstrated for AVB-S6-500, an ultra-high affinity decoy protein that binds to GAS6, in ccRCC trial, showed 46% best overall response rate in ITT population and 63% best overall response rate in sAXL/GAS6 biomarker high population.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
Updated results showed sustained efficacy and tumor shrinkage benefits with Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) compared to sunitinib for the treatment of patients with advanced renal cell carcinoma.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
Results of the previously treated advanced non-small cell lung cancer cohort of the phase 1b COSMIC-021 trial, we are eager to learn more about how cabozantinib in combination with atezolizumab may benefit this patient population.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
COSMIC-021 trial's New result of cabozantinib in combination with atezolizumab demonstrate a median progression-free survival in high-risk in patients with metastatic castration-resistant prostate cancer (CRPC).
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2021
Details:
Cabometyx (Cabozantinib) Tablet is a Multiple Receptor Tyrosine Kinases Inhibitor and Received U.S. FDA Approval of for Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
Cabozantinib is prescribed for treating patients with progressive, metastatic medullary thyroid cancer (MTC) and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2021
Details:
Approval based on the phase 3 CheckMate -9ER pivotal trial, which showed CABOMETYX in combination with OPDIVO improved overall survival and doubled median progression-free survival and objective response rate versus sunitinib.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2021
Details:
In the analysis of the primary endpoint of PFS in the PFS intent-to-treat population, cabozantinib in combination with atezolizumab significantly reduced the risk of disease progression or death by 37% compared with sorafenib.
Lead Product(s): Atezolizumab,Cabozantinib
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
Cabozantinib demonstrated a significant reduction in the risk of disease progression or death of 78% versus placebo in the intent-to-treat (ITT) population.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
This single-institution, non-randomized, open-label, investigator-sponsored, phase 2 trial of CABOMETYX 40 mg in combination with OPDIVO (240 mg every two weeks or 480 mg every four weeks) was conducted by Memorial Sloan Kettering Cancer Center.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2021
Details:
COSMIC-311 is evaluating Cabometyx® (cabozantinib) 60 mg versus placebo in people living with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 11, 2021
Details:
Approval based on Phase 3 CheckMate -9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall survival and doubled median progression-free survival and objective response rates compared to sunitinib.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2021
Details:
Cabometyx is approved for the treatment of patients with advanced renal cell carcinoma both as monotherapy and in combination with Bristol Myers Squibb’s Opdivo as a first line treatment. Cometriq is approved for progressive, metastatic medullary thyroid cancer.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $392.0 million Upfront Cash: $342.0 million
Deal Type: Divestment April 01, 2021
Details:
Cabometyx (Cabozantinib) Tablet is a Multiple Receptor Tyrosine Kinases Inhibitor and Received U.S. FDA Approval of for Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Details:
Recommendation based on the Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) doubled progression-free survival and significantly improved overall survival and response rates.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Details:
In the new findings, CABOMETYX demonstrated significant improvement in progression-free survival (PFS), the trial’s primary endpoint, and objective response rate (ORR) compared with sunitinib.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2021
Details:
Exelixis management and invited guests from the clinical community will discuss and provide context for cabozantinib clinical data presented at ASCO GU 2021, including updated results with extended follow-up data from CheckMate -9ER.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2021
Details:
In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
Details:
As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population.
Lead Product(s): Telaglenastat,Cabozantinib
Therapeutic Area: Oncology Product Name: CB-839
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2021
Details:
Per the terms of Exelixis and Takeda’s collaboration and license agreement, Exelixis is eligible to receive a $15 million milestone payment from Takeda upon the first commercial sale of CABOMETYX for unresectable HCC, which is expected to occur in the fourth quarter of 2020.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 27, 2020
Details:
The CELESTIAL trial was the basis for the CABOMETYX approvals in the U.S. and the EU for the treatment of patients with HCC who have been previously treated with sorafenib.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
Submission based on the CheckMate -9ER phase 3 pivotal trial, which showed CABOMETYX in combination with OPDIVO improved overall survival and doubled median progression-free survival and objective response rate versus sunitinib.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Applications based on pivotal Phase 3 CheckMate -9ER trial, which showed OPDIVO in combination with CABOMETYX improved overall survival, doubled median progression-free survival and objective response rate, and demonstrated a manageable safety profile.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Cabozantinib in combination with atezolizumab demonstrated promising preliminary efficacy and a favorable safety profile in cohorts of patients with clear cell and non-clear cell renal cell carcinoma.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
Opdivo in combination with CABOMETYX showed superior overall survival and doubled median progression-free survival and objective response rate with a favorable safety profile vs. sunitinib.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2020
Details:
Presentations will feature promising data across multiple cancers, including renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, prostate cancer and various neuroendocrine tumors.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
